Helicobacter pylori's cholesterol uptake impacts resistance to docosahexaenoic acid

International Journal of Medical Microbiology

Volumn 304, Issue 3-4, 2014, Pages 314-320

  Correia, Marta ^a,b,c   Casal, Susana ^a   Vinagre, João ^a,b   Seruca, Raquel ^a,b   Figueiredo, Ceu ^a,b   Touati, Eliette ^c   Machado, José C ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c INSTITUT PASTEUR   (France)

Author keywords

Bactericidal agents; Cholesterol; Helicobacter pylori; Mechanisms of resistance; PUFAs

Indexed keywords

CHOLESTEROL; DOCOSAHEXAENOIC ACID; ANTIINFECTIVE AGENT;

ARTICLE; AUXOTROPHY; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL SURVIVAL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EPITHELIUM CELL; GAS CHROMATOGRAPHY; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; LIQUID CULTURE; NONHUMAN; THIN LAYER CHROMATOGRAPHY; ANTIBIOTIC RESISTANCE; CELL LINE; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MASS FRAGMENTOGRAPHY; METABOLISM; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; CELL LINE; CHOLESTEROL; CHROMATOGRAPHY, THIN LAYER; DOCOSAHEXAENOIC ACIDS; DRUG RESISTANCE, BACTERIAL; EPITHELIAL CELLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HELICOBACTER PYLORI; HUMANS;

EID: 84899641976     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2013.11.018     Document Type: Article

References (34)

1. Applegate K.R., Glomset J.A. Computer-based modeling of the conformation and packing properties of docosahexaenoic acid. J. Lipid Res. 1986, 27:658-680.
2. Bergman P., Linde C., Putsep K., Pohanka A., Normark S., Henriques-Normark B., Andersson J., Bjorkhem-Bergman L. Studies on the antibacterial effects of statins - in vitro and in vivo. PLoS ONE 2011, 6:e24394.
3. Correia M., Michel V., Matos A.A., Carvalho P., Oliveira M.J., Ferreira R.M., Dillies M.A., Huerre M., Seruca R., Figueiredo C., Machado J.C., Touati E. Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization. PLoS ONE 2012, 7:e35072.
4. Correia M., Michel V., Osorio H., El Ghachi M., Bonis M., Boneca I.G., De Reuse H., Matos A.A., Lenormand P., Seruca R., Figueiredo C., Machado J.C., Touati E. Crosstalk between Helicobacter pylori and gastric epithelial cells is impaired by docosahexaenoic acid. PLoS ONE 2013, 8:e60657.
5. Dusserre E., Pulcini T., Bourdillon M.C., Ciavatti M., Berthezene F. Omega-3 fatty acids in smooth muscle cell phospholipids increase membrane cholesterol efflux. Lipids 1995, 30:35-41.
6. Gisbert J.P., Calvet X., O'Connor A., Megraud F., O'Morain C.A. Sequential therapy for Helicobacter pylori eradication: a critical review. J. Clin. Gastroenterol. 2010, 44:313-325.
7. Go G.W., Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med 2012, 85:19-28.
8. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
9. Hildebrandt E., McGee D.J. Helicobacter pylori lipopolysaccharide modification, Lewis antigen expression, and gastric colonization are cholesterol-dependent. BMC Microbiol. 2009, 9:258.
10. Hirai Y., Haque M., Yoshida T., Yokota K., Yasuda T., Oguma K. Unique cholesteryl glucosides in Helicobacter pylori: composition and structural analysis. J. Bacteriol. 1995, 177:5327-5333.
11. Knapp H.R., Hullin F., Salem N. Asymmetric incorporation of dietary n-3 fatty acids into membrane aminophospholipids of human erythrocytes. J. Lipid Res. 1994, 35:1283-1291.
12. Lai C.H., Chang Y.C., Du S.Y., Wang H.J., Kuo C.H., Fang S.H., Fu H.W., Lin H.H., Chiang A.S., Wang W.C. Cholesterol depletion reduces Helicobacter pylori CagA translocation and CagA-induced responses in AGS cells. Infect. Immun. 2008, 76:3293-3303.
13. Lee A., O'Rourke J., De Ungria M.C., Robertson B., Daskalopoulos G., Dixon M.F. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997, 112:1386-1397.
14. Lee H., Wang P., Hoshino H., Ito Y., Kobayashi M., Nakayama J., Seeberger P.H., Fukuda M. Alpha1,4GlcNAc-capped mucin-type O-glycan inhibits cholesterol alpha-glucosyltransferase from Helicobacter pylori and suppresses H. pylori growth. Glycobiology 2008, 18:549-558.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951, 193:265-275.
16. Malfertheiner P., Megraud F., O'Morain C., Bazzoli F., El-Omar E., Graham D., Hunt R., Rokkas T., Vakil N., Kuipers E.J. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007, 56:772-781.
17. McGee D.J., George A.E., Trainor E.A., Horton K.E., Hildebrandt E., Testerman T.L. Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37. Antimicrob. Agents Chemother. 2011, 55:2897-2904.
18. McMurray D.N., Bonilla D.L., Chapkin R.S. n-3 Fatty acids uniquely affect anti-microbial resistance and immune cell plasma membrane organization. Chem. Phys. Lipids 2011, 164:626-635.
19. Nseir W., Diab H., Mahamid M., Abu-Elheja O., Samara M., Abid A., Mograbi J. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate - a placebo-controlled study. Aliment. Pharmacol. Ther. 2012, 36:231-238.
20. Patel H.K., Willhite D.C., Patel R.M., Ye D., Williams C.L., Torres E.M., Marty K.B., MacDonald R.A., Blanke S.R. Plasma membrane cholesterol modulates cellular vacuolation induced by the Helicobacter pylori vacuolating cytotoxin. Infect. Immun. 2002, 70:4112-4123.
21. Peek R.M., Crabtree J.E. Helicobacter infection and gastric neoplasia. J. Pathol. 2006, 208:233-248.
22. Pelletier O., Wright L.A., Breckenridge W.C. Isotope dilution/mass spectrometry of serum cholesterol with [3,4-13C]cholesterol: proposed definitive method. Clin. Chem. 1987, 33:1403-1411.
23. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., Wagh U.V., Debsikdar V.B., Mahadik S.P. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003, 121:109-122.
24. Riff J.D., Callahan J.W., Sherman P.M. Cholesterol-enriched membrane microdomains are required for inducing host cell cytoskeleton rearrangements in response to attaching-effacing Escherichia coli. Infect. Immun. 2005, 73:7113-7125.
25. Rockett B.D., Franklin A., Harris M., Teague H., Rockett A., Shaikh S.R. Membrane raft organization is more sensitive to disruption by (n-3) PUFA than nonraft organization in EL4 and B cells. J. Nutr. 2011, 141:1041-1048.
26. Shaikh S.R., Dumaual A.C., Castillo A., LoCascio D., Siddiqui R.A., Stillwell W., Wassall S.R. Oleic and docosahexaenoic acid differentially phase separate from lipid raft molecules: a comparative NMR, DSC, AFM, and detergent extraction study. Biophys. J. 2004, 87:1752-1766.
27. Shimomura H., Hayashi S., Yokota K., Oguma K., Hirai Y. Alteration in the composition of cholesteryl glucosides and other lipids in Helicobacter pylori undergoing morphological change from spiral to coccoid form. FEMS Microbiol. Lett. 2004, 237:407-413.
28. Talley N.J., Fock K.M., Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am. J. Gastroenterol. 2008, 103:510-514.
29. Testerman T.L., Conn P.B., Mobley H.L., McGee D.J. Nutritional requirements and antibiotic resistance patterns of Helicobacter species in chemically defined media. J. Clin. Microbiol. 2006, 44:1650-1658.
30. Thompson L., Cockayne A., Spiller R.C. Inhibitory effect of polyunsaturated fatty acids on the growth of Helicobacter pylori: a possible explanation of the effect of diet on peptic ulceration. Gut 1994, 35:1557-1561.
31. Trainor E.A., Horton K.E., Savage P.B., Testerman T.L., McGee D.J. Role of the HefC efflux pump in Helicobacter pylori cholesterol-dependent resistance to ceragenins and bile salts. Infect. Immun. 2011, 79:88-97.
32. Wang H.J., Cheng W.C., Cheng H.H., Lai C.H., Wang W.C. Helicobacter pylori cholesteryl glucosides interfere with host membrane phase and affect type IV secretion system function during infection in AGS cells. Mol. Microbiol. 2012, 83:67-84.
33. Wunder C., Churin Y., Winau F., Warnecke D., Vieth M., Lindner B., Zahringer U., Mollenkopf H.J., Heinz E., Meyer T.F. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat. Med. 2006, 12:1030-1038.
34. Xiong Q., Lin M., Rikihisa Y. Cholesterol-dependent anaplasma phagocytophilum exploits the low-density lipoprotein uptake pathway. PLoS Pathog. 2009, 5:e1000329.